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Abstract
A liquid chromatography tandem mass spectrometry (LC-MSMS) method was
developed and validated to detect for the presence of zolpidem in human hair
samples. Zolpidem is a sedative hypnotic whose adverse effects make it a common drug
found in drug facilitated crimes (DFC). It is important to be able to detect and quantitate
the drug after a long period of time due to the victim’s delayed reporting of the
crime. Hair’s long window of detection makes it a useful matrix for DFC
investigations. The linear range of the assay was targeted at 2 pg/mg to 1,000 pg/mg and
experiments designed to test this range returned acceptable R2 values (> 0.985) in all
cases. The lower limit of linearity was established at 2 pg/mg. Accuracy and precision
of the assay were determined through replicate analysis of quality control samples. Both
intraday (n=3) and interday (n=15) accuracy and precision data were within acceptable
limits, +/- 20% error and 15% RSD. The matrix effect, recovery, and process efficiency
were determined to be 15%, 70%, and 10%, respectively. Additionally, the processed
sample stability of quality control samples at room temperature and dilution integrity of
spiked samples were found to be acceptable. No significant carryover was seen between
samples. This validated method was used to analyze authentic hair samples from donors
with reported zolpidem drug use as well as cosmetically treated samples spiked with
zolpidem. Results indicate possible interferences in the analysis of zolpidem in
cosmetically treated hair, but not authentic, untreated hair.
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1.  Introduction
Sleep-aids are commonly prescribed to help treat insomnia in the U.S. These sleepaids have been reported to facilitate crimes such as sexual assault (DFSA). Zolpidem
(Ambien) is one of these prescribed sleep-aids. Its fast-acting effects and short-duration
make it an effective agent for drug-facilitated sexual assaults. Since victims do not report
the crime in a reasonable amount of time, hair becomes the most important and beneficial
biological matrix. Hair samples can be analyzed to test for the presence of these drugs
after a period of time (months) have passed. A confirmatory liquid chromatography
tandem mass spectrometry (LC-MSMS) method has been developed and validated to detect
the presence of zolpidem in human hair samples.
Insomnia is a medical condition diagnosed in 5-15% of the North American and
United Kingdom population (Gunja, 2013). In the past, benzodiazepines have been used
to treat insomnia. Zolpidem (e.g. Ambien) has since replaced the use of benzodiazepines
for treatment because they have pharmacodynamic and pharmacokinetic advantages such
as a shorter duration of action and half-life. Zolpidem also does not disrupt sleep patterns
or cause residual effects. There is a low risk of dependence and abuse (Gunja, 2013).
Zolpidem’s effects are important when it comes to determining its use in drug facilitated
crimes.
Zolpidem is an imidazopyridine, a non-benzodiazepine.

It exhibits sedative-

hypnotic effects used to treat insomnia. A standard dosage, 10 mg for adults, is taken orally
prior to bed to reduce the time for sleep on-set. The on-set is seen within 15 minutes of
ingestion and has a half-life of 2-3 hours (Gunja, 2013). Once ingested, zolpidem is readily
absorbed by the gastric intestinal tract (GI) and metabolized in the liver. Cytochrome p450
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(CYP), metabolizes zolpidem into its inactive metabolites methoxyzolpidem and zolpidem
carboxylic acid (Gunja, 2013). CYP enzymes are part of the liver microsomal drugmetabolizing system which handles endogenous and exogenous compounds (e.g. drugs).
Specifically, for zolpidem, the CYP3A4 polymorph enzyme is responsible for oxidizing
the molecules so that they can be removed from the body. The primary pathway for
elimination is through renal excretion.
Similar to benzodiazepines, zolpidem binds to gamma-aminobutyric acid (GABA)
type-A receptors and exhibits sedative and hypnotic effects (Gunja, 2013). GABA is a
major inhibitory neurotransmitter in the central nervous system. It is a multi-component
transmembrane protein complex with multiple ligand binding sites. GABA-A is an
ionotropic receptor, with a ligand-gated chloride ion channel going across the membrane.
The complex contains multiple subunits including a (1), β (2), and γ. The subunits are
further divided into their own subunits (e.g. a1, a2, a3, and a5).

Zolpidem is a

benzodiazepine BZ1 (ω1) receptor agonist (Rust et al., 2012). Unlike benzodiazepines,
zolpidem selectively binds to the a1 subunit of the GABA-A receptor (Has et al., 2016).
The a1 subunit mediates sedation and amnesia as well as sleep regulation, while a2 and a3
mediate anxiety (Gunja, 2013). Once zolpidem binds to the GABA-A complex, it increases
the binding of the GABA neurotransmitter, thus increasing the frequency of the opening of
the chloride ion channel. When the channel is open, an influx of chloride ions enters the
cell causing membrane hyperpolarization. This moves the postsynaptic potential away
from the threshold, thus inhibiting propagation of an action potential, ultimately causing
inhibition of the central nervous system.
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There are possible adverse effects including hallucination and amnesia. Adverse
effects are increased with the use of zolpidem in combination with serotoninergic and
noradrenergic agents such as tricyclic antidepressants. Poisonings results in sedation and
coma. Deaths are rare and tend to occur with polydrug overdoses (Gunja, 2013).
In recent reports, there have been an increase in the misuse of zolpidem especially
with forensic cases, drug-facilitated crimes, and motor vehicle crashes (Gunja, 2013).
Hypnotic drugs such as zolpidem are effective agents for drug-facilitated sexual assaults
because they require a low dose, have a rapid on-set of action, and a short half-life (Rust
et al., 2012).

As mentioned, zolpidem acts on the central nervous system causing

symptoms of drowsiness. This is commonly found as the means of sedation in drug
facilitated sexual assault crimes.
A lot of the time, victims do not report the crime until well after the crime has taken
place due to the sedative effects of the drug or their fear of reporting the crime. Thus, in
order to examine the victim for exposure of the drug, the matrix studied must have a long
window of detection. In comparison to oral fluid, urine, and blood matrices, hair has a
longer window of detection of weeks to months. Hair is collected close to the scalp, at the
vertex posterior, where the hair growth rate is the most consistent (LeBeau et al., 2011).
Head hair has a known growth rate of 1 cm per month; however, the rate may change based
on various factors such as age, pregnancy, and hormones (LeBeau et al., 2011). With a
known rate, this allows for hair segmental analysis to determine the pattern of drug use
over a period of time (LeBeau et al., 2011). A one-time use can be seen with a short drug
band, while chronic use would show a longer band down the hair segment away from the
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root. In addition to having a broad detection window, hair testing has a lower risk of
adulteration, and an easier, non-invasive collection procedure.
Hair growth occurs it cycles. It begins at the follicle. Here, during the anagen
phase, cells divide, growing new hair and pushing the club hair out from the follicle. Hair
cells stop dividing, thus growth stops at the catagen phase. During the catagen phase, the
outer sheath of the hair attaches to the root forming the club hair. Lastly, the telogen phase
is when the hair follicle is at rest (LeBeau et al., 2011). The hair shaft is tough, yet flexible,
composed of elongated keratinized cells within a membrane complex. The membrane
complex is comprised of the cuticle, cortex, and medulla. The cortex provides the stability
and color composition.

Within the cortex, are melanocytes which produce melanin

pigments within melanosomes (Pragst & Balikova, 2006). The melanin is transferred to
keratinocytes where they are able to absorb light and give the hair color. Surrounding the
cortex are overlaying shingle-like cells containing pigmentation to the matrix, the cuticle.
The cuticle is also responsible for the chemical and physical resistance to the cell matrix
(Pragst & Balikova, 2006). In some hair, a medulla is present within the middle of the hair
shaft (LeBeau et al., 2011). Surrounding the outside of the hair follicle is a capillary system
which provides nutrients to the growing hair as well as a means of drug incorporation.
Drugs can become incorporated into the hair through various pathways. They can
enter through passive diffusion through the skin, blood capillaries, or sweat (Pragst &
Balikova, 2006). Another way is through external exposure from the environment or others
in the surrounding proximity. Drugs are deposited into the growing hair structure by
binding to proteins, melanin, or lipids of the membrane complex (Cui et al., 2013). Melanin
is the target of drug incorporation due to its ability to bind drugs. Long polymer strands of

5
dopaquinones form melanin.

These polymers contain carboxyl groups (acidic

characteristic) that are susceptible to donating a proton leaving a negative charge (Ghiani
et al., 2008). Positive charged ions have a greater affinity to melanin through electrostatic
interactions. The incorporation of basic drugs into hair has been seen (Kintz, 2007). There
have been some suggestions that the amount of melanin within the hair is related to the
amount of drug that is incorporated.

Based on this understanding, it is believed that

various hair colors, hair types, and cosmetic treatments will affect the drug’s incorporation.
The pKa of the compounds and the pH of the matrix cells are important because they
determine the degree of ionization of the acidic or basic compounds following protonation
or deprotonation.
In order to prevent external contaminants from causing positive hair results, the hair
undergoes extensive decontamination and washing procedures prior to analysis. Since
zolpidem is orally administered and not smoked, the metabolites do not need to be studied
to determine if zolpidem was present due to external smoke contamination.

The

decontamination and washing steps remove interferences from the surface of the hair
matrix such as hair products, dye, shampoo, exogenous analytes, and sweat.
Presumptive screening tests can initially be used to test for the presence of the drug
based on a cut-off concentration.

Enzyme-linked immunosorbent assay (ELISA)

commercial kits are a common screening technique used. Positive samples need to be
further analyzed using a more specific chemical method in order to confirm its presence
and concentration.
Instrumental analysis is more sensitive and requires samples to be cleaned prior to
analysis. Solid-phase extraction is used to free the drug from the hair matrix. Cartridges
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containing a solid stationary phase retain analytes using sorbent-analyte interactions.
These interactions include hydrophobic, hydrophilic, and electrostatic based on the
stationary phase and the analyte. In order to activate the polymer bed, a solvent is used to
condition it. Samples are loaded into the cartridges allowing for drugs to bind through
various mechanisms to the sorbent bed while unbound material is removed from the
cartridges. The cartridges are washed to remove excess material that is not bound to the
cartridges. Solvents are added in order to break the interactions holding the drugs to the
stationary phase of the column, freeing the drugs for analysis (Supelco, 1998). Solid-phase
extraction not only frees drug from matrices, but they clean-up the sample prior to
instrumental analysis.
Liquid chromatography tandem mass spectrometry (LC-MSMS) is the ideal
technique for confirmation testing. Liquid chromatography allows for various types of
samples to be analyzed as opposed to gas chromatography where the sample has to be in
the gaseous phase in order to be analyzed. The separation from LC is performed at a high
resolution. A solid stationary phase retains the analyte to the column, while the liquid
mobile phase pushes the analyte through the column. Separation of the components is
based on polarity between the solid and liquid phases. Tandem mass spectrometry allows
for the sensitive detection of trace amounts of drug. An ionization source is used to remove
the solvent from the sample and create small gas phase ions in a vacuum. Electrospray
ionization is a common ion source used prior to mass spectrometry. In this source, the
solvent and analyte compete for space inside of a droplet. Positive charge builds up and
blows apart to form small ions in an aerosol. The ions are then attracted into the mass
spectrometer through vacuum and magnetic fields. Once inside, the ions travel to the first
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mass analyzer and are separated by their mass-to-charge ratio. Ions that meet the qualifying
ratio are the “parent” ions. The “parent” ions then move to the collision cell where they
come into contact with N2 molecules and break apart to form “daughter” ions. The
“daughter” ions move to the final mass analyzer where they are separated based on their
mass-to-charge ratio (Skoog et al., 2007). Since multiple transitions (parent to daughter
ions) are being monitored, the mode of the mass spectrometer is in multiple reaction mode
(MRM). A qualifier and quantifier transition are used to detect and then quantify the
analyte present. The combination of the liquid chromatography with mass spectrometry
results in a rapid, specific, sensitive, and robust method for confirmatory testing.
Other studies for the detection of zolpidem in hair using LC-MSMS have been
done. In one study, Kim and authors used 10 mg of washed hair (a methanol and deionized
water wash) followed by a methanol digestion at 38 ºC for 16 hours. To extract the drug,
the substrate was evaporated and the residue was reconstituted with methanol and mobile
phase A and then filtered through a polyvinylidenefluoride (PVDF) microporous
membrane prior to LC-MSMS injection (Kim et al., 2011). Their LC-MSMS method had
a linear working range of 0.25 – 5 ng. For zolpidem, the LOD was 0.005 ng totoal and the
LOQ was 0.25 ng total. Matrix effect was an average of 88% and 90% for the LOD and
LOQ, respectively. Recovery was 93% and 89%, respectively. Process efficiency was
81% and 79%, respectively (Kim et al., 2011). Based on the results, there is a significant
matrix effect seen due to ion suppression. Another hair analysis of zolpidem involved in
drug facilitated crimes by Salamone and authors used 100 mg of hair, washed the hair
(dichloromethane) and incubated the samples in methanol for 15 hours at 55 ºC. The
organic phase was collected, evaporated, and reconstituted with the mobile phase. The
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working linear range was 2 – 100 pg/mg, the matrix effect was -4.7% (compared the peak
area of 25 pg/mg spiked into hair to the peak area of a methanolic standard at the same
concentration) (Salomone et al., 2012).
The goal of the present project was to develop and validate a sensitive and efficient
LC-MSMS analysis for the quantitative detection of zolpidem in hair. The established
method would be validated using various standard procedures to ensure it is acceptable for
clinical and forensic laboratory usage. This LC-MSMS method can then be applied to
solving various cases including drug facilitated crimes.

2. Materials  
2.1. Chemicals and Reagents.

Zolpidem (1.0 mg/mL in 1 mL methanol) (Z-017 Lot: FE04251603) and Sedative
hypnotics internal standard, containing zolpidem-d6 (Lot: IS1603-17SED (1)) were
purchased from Cerilliant (Texas, USA) and were stored in the fridge. HPLC grade
methanol, dichloromethane, and isopropanol were obtained. Phosphate buffer, pH 6.0,
pouches were from United Chemical Technologies (Bristol, PA). Ammonium hydroxide
reagent was from Spectrum Chemical Manufacturing Corporation. Glacial acetic acid and
sodium hydroxide pellets were from Sigma-Aldrich. Hair extraction buffer (HEB) was
purchased from Immunalysis (Pomona, CA).
2.2. Standard Solutions

Working standard solutions were prepared using the purchased certified stocks of
zolpidem (at 1 mg/mL in methanol) and sedative hypnotics internal standard. A working
solution of internal standard at a concentration of 100 ng/mL was prepared in deionized
water by the dilution of 10,000 ng/mL stock solution. Zolpidem working standards were
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prepared at concentrations of 100,000 ng/mL, 10,000 ng/mL, 1,000 ng/mL, 100 ng/mL, 10
ng/mL, and 1 ng/mL in methanol by serial diluting the zolpidem 1 mg/mL standard stock
solution.
2.3. Specimen

Negative hair including cosmetically treated samples were provided by Cordant
Health Laboratory for drug analyses. They were tested negative by using a LC-MSMS
analytical method. The samples were decontaminated as described later (section 3.1) to
remove contamination that could interfere with the analyses. Authentic donor hair samples
with reported zolpidem drug use were obtained from the University of Pennsylvania for a
matrix correlation project. This project used anonymous, consented donor samples (oral
fluid, urine, plasma, and hair, if applicable) to determine if there was a drug concentration
correlation seen between the various sample matrices for a given drug.

3. Methods
3.1. Sample Decontamination

Hair samples were first decontaminated to remove contaminants such as dye,
sebum, shampoo, and any other external interfering agents. A clump of hair was placed
into a beaker with dichloromethane covering the top of the hair. The solution was swirled
for 2 minutes, decanted, and dried under a light flow of nitrogen. Isopropanol was added
covering the hair, the solution was swirled for 2 minutes, and decanted. Then methanol
was added covering the hair, the solution was swirled for 2 minutes, decanted, and dried
under a low flow of nitrogen. The hair was stored in a folded piece of paper inside of an
envelope and left in a drawer at room temperature until analysis.
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3.2. Method Development: Hair Digestion

Fortification of the hair was performed to ensure that the hair would be positive for
zolpidem when developing the LC-MSMS method. A solution of dH2O: DMSO (1:1) was
added to 5 g of decontaminated hair. Zolpidem was spiked at 100 times the expected cutoff (20 pg/mg). In addition, to increase the total volume, 5 mL of 100,000 ng/mL, 1 mL
of deionized water, and 1 mL of DMSO were added. The hair was soaked and sonicated
every 2-3 days. After 5 days, the hair tested positive using a LC-MSMS method.
Hair extraction buffer (HEB) and 1M sodium hydroxide were both tested to
determine which digestion solution recovered the most amount of drug. Two sets of
fortified hair samples were prepared (30 mg). The samples were washed with 3 mL of
methanol and twice with 3 mL of phosphate buffer (pH 6.0), each time vortexed,
centrifuged, and decanted, except for the last wash with phosphate buffer. The last wash
was saved to determine the efficiency of the washing procedure. In one set of samples, 1
mL 1M sodium hydroxide was added, vortexed, and centrifuged. The tubes were placed
into a hot block for 30 minutes at 70 °C. After, they were cooled to room temperature and
180 µL of 20% acetic acid was added, vortexed, and centrifuged. In the second set of
samples, 1 mL of HEB was added to the tubes, vortexed, and centrifuged. The tubes were
then incubated for 2 hours at 75 °C. After they were cooled to room temperature, 1 mL
phosphate buffer (pH 6.0) was added, vortexed, and centrifuged. Each set’s supernatant
was removed, spiked with internal standard, extracted with the solid-phase extraction
method, dried down with nitrogen, reconstituted with 0.1% formic acid, and injected into
the LC-MSMS for analysis.
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3.3. Hair Digestion and Cleanup

Decontaminated hair samples (30 mg) were cut into small pieces (~1 mm) and
aliquoted into 12 x 75 mm tubes. The samples were washed to ensure that all interferents
were removed for a clean LC-MSMS anlysis. The hair was washed with 3 mL of methanol
(vortex and centrifuged for 5 min. at 4200 rpm) and decanted, and twice with 3 mL of
phosphate buffer (pH 6.0) (vortex and centrifuged for 5 min. at 4200 rpm) and decanted.
This cleans the hair from any external contamination that they might have come into
contact with. The washed cut hair was then spiked to create a zolpidem working range (2
pg/mg to 1,000 pg/mg) (Table 1). A sedative hypnotic internal standard (60 µL of 100
ng/mL) was also added to each sample.
Table 1. LC-MSMS Calibrator Spiking Chart.
Level

Target
Concentration
(pg/mg)
Negative Control
0
1
2
2
5
3*
10
4
20
5*
50
6
100
7*
200
8
500
9
1000
*Quality Control (QC)

Stock
(ng/mL)
---1
10
10
10
100
100
100
1000
1000

Spiking
Volume
(µL)
------60
15
30
60
15
30
60
15
30

For the digestion of the hair, a 1 mL aliquot of 1 M NaOH was added and the
samples were vortex and centrifuged at 4200 rpm for 5 minutes. The samples were
incubated for 30 minutes at 70°C in a hot block. Neutralization followed with 180 µL of
20% acetic acid, vortex, and centrifuged at 4200 rpm for 5 minutes. The supernatant was
then removed from the tubes and the analytes were ready for extraction.
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Solid-phase extraction of the drug was performed using an automated liquid
dispenser (ALD) and Strata-XC cation exchange cartridges.

The cartridges were

conditioned with methanol and water, and then flashed with N2 gas for 19 seconds to lightly
flush out the contents. A LEUR seal was attached and 0.1 M phosphate buffer was added.
The samples were then loaded and the LEUR seal was removed. Next, the cartridges were
washed by first flushing out the contents with N2 gas followed by the addition of water and
25% methanol, and another flushing with N2 gas. The cartridges were left to dry for 14
minutes under a low nitrogen flow. After drying, an elution solvent of dichloromethane:
isopropanol: ammonium hydroxide (70:26:4) was added to the cartridges to allow the free
drug to elute into autosampler vials. The vials were then placed in a concentrator under a
low nitrogen flow at 40°C for about 15 minutes until the vials were completely evaporated.
Next, the vials were reconstituted with 50 µL of the mobile A phase: 1% formic acid and
vortexed. The vials were then loaded onto the LC-MSMS for analysis.
3.4. LC-MSMS Instrumental Analysis

The LC-MSMS confirmatory analysis was performed on an Agilent 1290 liquid
chromatograph with 6460 triple quadrupole mass selective detector. An LC-MSMS was
used for confirmatory testing because it provides a high throughput and sensitive analysis.
The Agilent instrument uses two columns simultaneously that are connected by a switch
valve to avoid the use of post-column switching and the associated dead volume. Also, the
use of two columns working simultaneously allows for the analysis and re-equilibration of
a second column. This saves the time of switching and cleaning columns as well as
increasing the throughput. A Kinetex® 2.6 µm Biphenyl 100 Å Column; 50 x 2.1 mm
reverse phase column was used. The biphenyl column has strong pi-pi interactions and is
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non-polar. This is good for the retention of hydrophilic aromatic compounds (Kinetex
Biphenyl, n.d.). A set method “Sedative Hypnotic Hair” was optimized and used for
analysis. The following are the method’s parameters:
Injection: 20 µL
Mobile Phase
Mobile Phase %A: Water
Mobile Phase %B: Methanol
Mobile Phase Composition:
Time
(min.)
0.00
0.30
1.20
2.00
2.01

B
[%]
30.00
30.00
60.00
60.00
30.00

Flow
(mL/min.)
0.700
0.700
0.700
0.700
0.700

Column
Temperature: 50 °C
Triple Quadrupole MS Parameters
Acquisition Mode: ESI (+ ion)
Multiple Reaction Monitoring Table:
Internal
Compound Name
Standard

Precursor Product
Ion
Ion

Fragmentor

Collision
Energy

Zolpidem d6
Zolpidem
Zolpidem

314.2
308.2
308.2

175
150
150

80
36
80

√

65.1
235.1
65.1

Cell
Accelerator
Voltage
7
7
7

Polarity
Positive
Positive
Positive
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ESI Source Parameters
Gas Temperature: 350 °C
Gas Flow: 10 L/min.
Nebulizer Pressure: 50 psi
Sheath Gas Temperature: 400 °C
Sheath Gas Flow: 11 L/min.
Capillary Voltage: 4000 V Positive 4000 V Negative
3.5. Method Validation

Validation of the confirmatory method using LC-MSMS contains various
procedures that have to be completed in order to validate that the developed method works
prior to being used in the laboratory. The analytical method was validated using spiked
negative decontaminated hair and the following parameters were evaluated: accuracy and
precision, linearity and sensitivity, matrix effect, recovery, and process efficiency,
carryover, dilution, stability, selectivity, and proficiency testing.
First, accuracy and precision testing were performed by preparing and examining
qualitative controls (10, 50, 200 pg/mg) in triplicates (intraday) and in triplicates for over
five days (interday). Accuracy (bias) compares the expected result with the measured
result.

Systematic error can result in deviations between the two results. Precision

measures the closeness of the samples performed in replicates. If deviations are seen,
random errors can be the cause. The coefficient of variation (CV) is used to measure the
accuracy and precision of the data. Acceptable data for each analysis is a %CV <10.
Linearity and sensitivity were examined by preparing calibration curves once per
day over the course of five days to evaluate their linear range. The concentration of the
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analyte in the matrix over the range of analyte concentrations being studied (the working
range) has to be directly related to the response of the method in order for there to be
linearity. Thus, the working range has to be tested to ensure it is in linear range. Validation
was complete when all of the samples fell within 15% of their expected values and the
curve r2 values were above 0.985.
Matrix effect was examined next to determine the %recovery, the interference of
the hair matrix, and the process efficiency of the extraction technique. Three groups were
created at the same midway concentration (100 pg/mg) with no internal standard added:
neat un-extracted (Group A), post-extraction standards (Group B), and pre-extraction
standards (Group C). Group A consisted of three neat un-extracted standards, Group B
consisted of prepared and extracted samples in triplicates for five different sources, and
Group C consisted of prepared samples in triplicates for five different sources. Matrix
effect involves the alteration or interference of an unintended analyte or substances in the
sample matrix which changes the response of the LC-MSMS instrument. The intended
analyte in the sample matrix has to be tested to ensure there is no interference. This is done
by examining the recovery, process efficiency, and ultimately the matrix effect. Once there
is high recovery and process efficiency and a low matrix effect, the data can be accepted.
The efficiency of the LC-MSMS method was looked at next by determining
whether or not there was sufficient carryover taking place. High concentrations of sample
remaining in the column and eluting with a lower concentration can cause problems when
analyzing the data. In order to determine if this is occurring and to determine how much
is being carried over, two samples containing the upper limit of linearity (ULOL) and 10
times the ULOL were prepared (1,000 pg/mg and 10,000 pg/mg respectively) as well as
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two negative controls. The ULOL and the 10x ULOL samples were injected into the LCMSMS. Following each, a negative control was injected. If there is a significant amount
of carryover, the LC-MSMS method would be adjusted to correct it.
The stability of the samples at room temperature were examined next over three
days. A set of QCs was prepared (doubled everything throughout the experiment to ensure
that there was enough sample to examine over three days). The extraction and instrumental
analysis of the samples were performed for the first day. The remaining sample aliquot
was then left out at room temperature to be injected for a second day and then repeated for
a third day. Stability testing is performed to show that the samples are stable throughout
the procedure as well as during storage, if left at room temperature prior to analysis.
Comparing freshly made samples with those that have sat out over time can demonstrate
its stability.
Dilution testing is to ensure that the quantities that are being analyzed are accurate
if a dilution is necessary if the concentration goes beyond the linear working range or less
sample is available. The ULOL was prepared at dilution factors (DF) of 2, 4, and 10, by
diluting with the 1M NaOH solution. Dilutions were added prior to digestion. All values
are accepted if their quantities, with dilution factors, are within +/- 15% of the expected
values.
Selectivity study is done to test the method’s ability to select for only the
compounds of interest and not the interferences in the matrix, standards, internal standard,
or other analytes that might be present in the sample. This study uses negative hair samples
from different sources. Three replicates of each source are prepared without standard or
internal standard to test for the presence of any compound within the matrix itself. This
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will ensure that the hair is purely negative. Next, three replicates of each hair source are
prepared with only internal standard at the concentration used in the calibration curve (60
µL of 100 ng/mL). This was to see if there was a standard response present from internal
standard impurities. Lastly, each of the five sources of hair were washed. In five separate
tubes, one at a time, 1 mL of 10,000 pg/mg of five different analytes (benzoylecgonine,
oxazepam, hydrocodone, imipramine, and lorazepam) were added and dried down with N2.
After all of the analytes were dried down, the tube residues were reconstituted with 1 mL
of 2 pg/mg of zolpidem calibrator and spiked with internal standard. The reconstituted
solutions were added to the source samples. The samples were then digested with 1 mL of
1M NaOH, neutralized, and extracted. The analytes were chosen from the College of
American Pathologists’ “Master List” of common drug facilitated compounds. The data
was analyzed to see if the LOQ properly quantitates in the presence of other compounds.
Proficiency testing is performed using samples prepared by a Research and
Development staff member. Hair samples are spiked with a known concentration of
zolpidem by a reputable source. The concentration is unbeknownst to the scientist who
will then test and analyze the sample. Extraction and proficiency testing is implemented
in order to test the method as well as the scientist, to ensure that they are working properly.
The scientist’s quantitative results are then compared to the known reputable results to
determine the efficiency of the method and the scientist.
Authentic, reported zolpidem positive, hair samples were obtained from the
University of Pennsylvania in collaboration of a biological matrix correlation experiment.
A study between Cordant Health Solutions and University of Pennsylvania is being
conducted to quantify urine, oral fluid, plasma, as well as hair samples for a wide range of
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drugs and correlate the concentrations within the four matrices. These samples were
obtained from anonymous donors who also reported their medical history for the study.
The samples did not contain any markers that would identify the donor. An aliquot of the
positive zolpidem hair samples was analyzed using the LC-MSMS method developed. The
zolpidem hair concentrations were compared to the other matrices zolpidem
concentrations.

4. Ethics
Since this method development research involves human subjects, informed
consent, information regarding the research, and additional protections will be required
from the subjects. Cordant Health Solutions, where this research is being performed,
typically request positive samples from other drug testing labs as their human subject
samples for validation work. All of the samples are de-identified and lack any protected
health information (PHI) in accordance with the Health Insurance Portability and
Accountability Act (HIPAA) privacy rule.

The research being conducted is in an

acceptable manner, applied towards the planning, execution, and reporting. It is being
performed ethically to protect the interest of the individuals involved and followed all
federal, professional, and institutional guidelines and regulations.

5. Results
5.1. Method Validation

The developed LC-MSMS method produced a good separation and detection of the
zolpidem analyte over the calibration range (2 to 1,000 pg/mg). The zolpidem and its
deuterated form’s structures are seen in Figure 1.
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Figure 1. Zolpidem (left) and its deuterated form (right).
A representative chromatogram of zolpidem with internal standard in hair is
shown in Figure 2. The peak of zolpidem is shown to elute at 1.3 ± 0.2 minutes. The
parent ion of zolpidem has a mass-to-charge ratio of 308.2 m/z and two product ions of
235.1 m/z and 65.1 m/z (Figure 3).

Figure 2. LC-MSMS representative chromatogram of zolpidem in blank spiked hair.

Figure 3. LC-MSMS representative spectrum showing zolpidem ion fragments
(m/z 308.2 à 235.1) and (m/z 308.2 à 65.1).
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A comparison between a 1M sodium hydroxide and hair extraction buffer (HEB)
digestion was performed with the fortified hair to determine which had a higher drug
recovery. The last wash was also saved to see how well the washing procedure worked.
The wash consisted of a methanol and phosphate buffer wash. Table 2 shows the results
of the washing procedure as well as the difference in recovery after both digestion methods.
Zolpidem was recovered, after a 1M NaOH digestion, at a concentration five times great
than that of an HEB digestion. The low concentration of zolpidem seen in the last wash
indicates a good washing efficiency. Figure 4 depicts the comparison between the two
digestion methods and the efficiency of the last wash.
Table 2. Wash Efficiency and Recovery After Digestion (1M NaOH vs HEB)
Sample Digestion Solution Concentration (pg/mg)
1 – LW
NaOH
14
2 – LW
NaOH
13
3 – LW
NaOH
14
1–H
NaOH
5063
2–H
NaOH
5137
3–H
NaOH
8269
1 – LW
HEB
12
2 – LW
HEB
14
3 – LW
HEB
12
1–H
HEB
1164
2–H
HEB
1148
3–H
HEB
1020
*LW- last wash, H- hair
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Zolpidem  Concentration  (pg/mg)  

Washing  Procedure  and  Extraction  Recovery  After  a  NaOH  v  
HEB  Digestion
8297
9000

7252

8000

6287

7000
6000
5000
4000
3000
2000
1000

1164
14

13

1021

1148
15

13

15

13

0
NaOH  LW

NaOH  Hair

HEB  LW

HEB  Hair

Figure 4. Washing efficiency and extraction recovery of zolpidem after a 1M NaOH and
HEB digestion.
Since the 1M sodium hydroxide had a higher recovery, it was used as the digestion
solution for the LC-MSMS analysis. The recovered concentration post-digestion shows
how well the fortification procedure worked in incorporating the drug into the hair as well
as how well the recovery of the drug from the digested matrix worked.
Validation of the developed assay was tested using decontaminated negative hair
(30 mg) samples and performing various validation procedures. The hair was validated
over a concentration range of 2 to 1,000 pg/mg. The calibration curves were prepared
using either quadratic or linear formulas to produce a best fit line with good r2 values.
Good linearity was obtained when the r2 was greater than 0.985 (Table 3). This was seen
in all five days of linearity testing as well as in all other analyses.
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Table 3. Linearity of Calibration Curves.
Calibration Curve Formula
Day
y = -0.003111x2 + 0.459669x – 0.002492
1
y = -0.009311x2 + 0.726733x – 0.002477
2
3
y = -0.002977x2 + 0.230380 + 0.011476
y = 0.002845x2 + 0.250983x + 0.003026
4
y = -0.002611x2 + 0.586466x + 0.013747
5
R2 values are weighted: 1/x^2

2

R
0.9854
0.986
0.9973
0.9959
0.995

The intraday (n = 3) and interday (n = 15) precision and accuracy (bias) results for
zolpidem at the quality control concentrations (10, 50, and 200 pg/mg) are seen in Table 4.
The accuracy and precision data were within acceptable limits, +/- 20% error and 15%
RSD. The intraday precision and accuracy of the 10 pg/mg, 50 pg/mg, and 200 pg/mg QCs
were 4% and 10%, 9% and -1%, and 2% and 2%, respectively. The interday precision and
accuracy of the 10 pg/mg, 50 pg/mg, and 200 pg/mg QCs were 9% and 2%, 9% and 4%,
and 11% and 6%, respectively.
Table 4. Intraday and Interday Precision and Accuracy of Zolpidem in Quality Control Hair
Samples.
Concentration (pg/mL)
Statistical Variable
10
50
200
Intraday (n = 3)*
11.0344  
49.6598  
203.7433  
Mean
4.1165  
9.3734  
2.1176  
Precision (%RSD)
10.3437  
-‐0.6805  
1.8716  
Bias (%RE)
Interday (n = 15)**
10.186  
51.998  
212.608  
Mean
8.640  
8.889  
11.418  
Precision (%RSD)
1.863  
3.996  
6.3039  
Bias (%RE)
*Intraday results from Day 3
**Interday results are the average of the 15 samples over 5 days
Precision (%RSD) = ([mean]/ SD) *100
Bias (%RE) = ([mean calculated] – [expected])/ ([expected]) *100
The matrix effect, extraction recovery, and process efficiency were performed
twice since the results were not expected (Table 5). The matrix effect for the five sources
was observed to be on average 15% over the two days. The extraction recovery and process
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efficiency of the method for five sample sources averaged 70% and 10%, respectively over
the two days.
Table 5. Matrix Effect, Extraction Recovery, and Process Efficiency (100 pg/mg).
Day 1
Source
(Color)

%
%
Matrix Extraction
Effect Recovery

Day 2
% Process
Efficiency

%
Matrix
Effect

%
Extraction
Recovery

% Process
Efficiency

1 (N/A)

19

55

10

23

56

13

2
(Black)

10

63

6

16

86

13

3 (N/A)

13

68

9

10

83

8

4
(Blonde)

17

73

13

16

81

13

5 (Light
Brown)

13

97

12

14

57

8

Average

15

70

10

16

71

11

%Matrix Effect = (Post-Addition/ Neat) *100
%Recovery = (Pre-Addition/ Post-Addition) *100
%Process Efficiency = (Post-Addition/ Neat) * 100
The process sample stability of zolpidem in hair was stable over five days at room
temperature after the analysis of three samples at quality control concentrations (10, 50,
and 200 pg/mg). Figure 5 shows the stability of the QCs over five days. Analysis of the
samples was on Day 1. The samples were then left out at room temperature and re-analyzed
on Days 2 and 5.
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Quality  Control  Porcess  Stability

225

Concentration  (pg/mg)

200

QC  10

175
150

QC  50

125
100

QC  200

75
50
25
0
25-‐Mar

26-‐Mar

27-‐Mar

28-‐Mar

29-‐Mar

30-‐Mar

31-‐Mar

Day  of  Analysis

Figure 5. Stability of QCs 10, 50, and 200 pg/mg over five days. Samples were analyzed
on Days 1, 2, and 5.
The dilution integrity showed accurate results between the expected and actual
concentrations (Table 6). The measurements of the diluted samples were within +/- 15%
of the theoretical concentration.
Table 6. Dilution Integrity.
Expected
Actual
Sample Dilution Concentration Concentration %Accuracy
(pg/mg)
(pg/mg)
ULOL

N/A

1000

1035

-3.5

DF 2

1:1

500

525

-5

DF 4

1:3

250

264

-5.6

DF 10

1:9

100

108

-8

Carryover is analyzed to ensure that there is not leftover analyte in the analytical
instrument after analysis. The carryover was evaluated by analyzing two blank samples
followed by high concentrations (1,000 and 10,000 pg/mg). The two blank samples
showed low responses with noise compared to the upper limits’. Table 7 shows the
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carryover results for the ULOL, 10x ULOL, and the negative controls between analyses.
Figure 6 shows the blank chromatograms after the ULOL and 10x the ULOL. There was
not a qualifier ion detected and only noise peaks were visible.
Table 7. Carryover results of the LC-MSMS.
Internal
Zolpidem
Samples
Standard
Response
Response
ULOL

3124205

1099794

Blank 1

3858.98

1022388

ULOLx10

4.5E+07

534712

Blank 2

29757

946740

A
B
Figure 6. Blank sample chromatograms after the ULOL (A) and after 10x ULOL (B)
showing noise peaks and no qualifier detected.
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The selectivity study showed that the hair matrix alone did not contain any
endogenous and exogenous matrix interferences. The potential of endogenous matrix
interferences was assessed using five blank hair samples fortified with internal standard
previous to this experiment. Exogenous matrix interferences were assessed by the analysis
of five blank hair samples fortified with five common drugs used to facilitate crimes at
10,000 pg/mg, as well as 2 pg/mg of zolpidem (LOD). The five drugs that were tested
were benzoylecgonine, oxazepam, hydrocodone, imipramine, and lorazepam.

The

analytical method was able to measure and differentiate the zolpidem analyte and internal
standard in the presence of the five other compounds at high concentrations within the hair
samples. Table 8 shows the analyte and internal standard response, as well as the detected
zolpidem concentration after the analysis of the five samples. The 2 pg/mg zolpidem were
detectable in samples 1-3, not in samples 4 and 5. The method was selective to those two
samples since the analyte was not detected less than the LOD. Figure 7 depicts the
chromatograms of the five samples for the zolpidem analyte m/z (308.2 à 235.1) and
internal standard (m/z 314.2 à 65.1).
Table 8. Selectivity Study of Five Hair Samples with Five Other Compounds.
Samples*
Samples
Analyte
Internal
Concentration
Response
Standard
of Zolpidem
Response
(pg/mg)
Zolpidem (2 pg/mg),
1
57700
1269040
2.3736
Internal Standard, and
2
41195
1129552
1.6104
Five Other Compounds
3
72511
1459572
2.7309
4 (dyed red
28308
1309256
0.3509
hair)
5 (dyed red
15364
850157
0.0498
hair)
*Samples were tested analytically prior to determine they were negative.
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1

2

3

4
5
Figure 7. Chromatograms showing the zolpidem peak for samples 1-5.
The proficiency testing of spiked hair samples prepared by a research scientist at
Cordant Health, were consistent with the expected results (Table 9). The results were +/15% of the actual concentrations.
Table 9. Proficiency Testing.
PT Actual PT Results
PT #
(pg/mg)
(pg/mg)

% Accuracy

1

7.5

6.0147

-19.80

2

25

23.9360

-4.26

3

75

76.8704

2.49

4

250

247.8854

-0.85

5

750

752.1665

0.29
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5.2. Clinical Application

Authentic hair samples, positive for zolpidem, were obtained from the University
of Pennsylvania. The samples were analyzed using the developed method in collaboration
with their on-going biological matrix correlation study. The study used anonymous donor
patients’ urine, oral fluid, plasma, and hair samples. The patients’ medical history was
noted. Samples 022 and 210 were weighed (30 mg and 15 mg (DF 2), respectively) and
internal standard was added.

The method’s digestion, extraction, and LC-MSMS

procedures were performed.

Zolpidem was detected in samples 022 and 210 at

concentrations of 578 pg/mg and 834 pg/mg, respectively (Table 10). The correlation
between the biological matrices is seen in Table 11.
Table 10. University of Pennsylvania Correlation Study: Hair Analysis
Sample

Zolpidem

022

1

Calculated
Final
Concentration Concentration
0.994 10139665
577.9367
577.9367

210

2

0.994 10147782

SID Dil.

RT

Response

417.2332

834.4664

Qualifier

Zolpidemd6

RT

Response

0.981

1570265

0.984

2172406

Table 11. University of Pennsylvania Biological Sample Correlation for Zolpidem.
SID

[Urine]
(ng/mL)

022

65.6668

[Oral
Fluid]
(ng/mL)
2.3989

210

4.2222

5.7796

[Plasma]
(ng/mL)

[Hair]
(pg/mg)

56.9612

577.9367

14.7416

834.4664
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6. Discussion and Conclusion
The LC-MSMS method developed to detect the presence of zolpidem, a sedativehypnotic, in hair samples has been efficiently validated. The zolpidem was seen to elute
within approximately 1.3 minutes, with a total run time of 2 minutes.
A wash using methanol and phosphate buffer has shown to successfully remove
external contamination on the surface of the hair. The last wash that was analyzed from
the fortified samples, showed low levels of drug compared to the amount of recovered
drug. The wash though, was not tested on interferences including dye, bleach, and other
common cosmetic chemicals. The influence of cosmetic treatments of hair on drug testing
has been of concern for drug analysis in hair. Products that are strong bases are expected
to cause damage to hair (Jurado et al., 1997). More specifically, damage to melanin within
the hair follicle. Thus, drugs may be lost from the matrix.
The digestion, using sodium hydroxide was seen to show a better drug extraction
than hair extraction buffer. Other digestion methods can possibly be tested that do not
require a neutralization step such as methanol or an enzyme extraction. The neutralization
step, can be difficult since there can be variability with pH between sources causing the
amount of neutralization solution to vary. The solid-phase extraction using Strata exchange
columns and the method used has shown to extract the zolpidem, basic drug efficiently.
The linearity, intraday and interday precision and accuracy, carryover, process
sample stability, dilution integrity, and proficiency testing parameters yielded satisfactory
results for the detection of zolpidem. Matrix effect and selectivity showed results that were
not expected but are accepted since they have known causes that can be investigated.
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Matrix effect was seen throughout all of the hair samples. As a result of matrix
effect, process efficiency was expected to be low due to 85% ion suppression. Ion
suppression is a form of matrix effect that is seen with liquid chromatography-mass
spectrometry. Modifying the instrumental component parameters and sample preparation
can be considered to reduce or possibly eliminate ion suppression. A cleaner extraction
technique can be further investigated. This method is subject to significant matrix effects,
but with the exception of dyed hair samples, the method is sensitive enough to quantitate
2 pg/mg in hair samples.
In the selectivity procedure, it was difficult to detect the LOD in samples 4 and 5.
This may be due to these samples being cosmetically treated with dye. Cosmetic treatments
interfere with the melanin structure, thus altering the incorporation of drugs into the hair
matrix. There was limited authentic samples available for this research. Some of the
samples available were cosmetically treated. Future studies are required to determine the
effect cosmetically treated hair has on drug analysis.
The hair samples in the University of Pennsylvania correlation study were found to
have higher zolpidem concentrations than that in the other three matrices. There does not
appear to be a correlation trend between zolpidem within the various biological matrix
samples.
Overall, this developed and validated confirmatory LC-MSMS method, compared
to previous methods, is more sensitive with an LOQ of 2 pg/mg, quicker with a digestion
of 30 minutes, and easier with a fast and automated extraction procedure (Salomone et al.,
2012) (Kim et al., 2011). This method is useful for the quantitative detection of zolpidem
in hair samples.
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The method developed was to detect the presence of zolpidem in hair samples. A
dosage study and segmental analysis was not performed. A control study is needed to
analyze hair samples after a single, low-dosage of zolpidem. This will determine if the
LOQ that was established in this method is acceptable for the low, single-dosage of
zolpidem for a facilitated crime.

7. Future Research
A future development of an ELISA screening technique would allow for an easy
initial detection of zolpidem within hair samples. The zolpidem commercial plates that are
already available are not compatible with complex matrices such as hair samples. As a
result, various sample sizes, digestion methods, and solution volumes have to be studied.
Also, a phosphate buffered saline wash might help to remove the non-specific binding, thus
lowering the possible presence of interferences and increasing the absorbance.
The effects of various cleaning agents (e.g. shampoo, conditioner) as well as
chemical and physical agents (e.g. dye, bleach, heat) should be studied. Two samples that
were analyzed in this experiment were red-dyed hair. The dye might have altered the
melanin structure within the hair, thus affecting the ability to detect the low levels of drug.
Cosmetically treated samples should be analyzed as to how to better wash and extract low
levels of analytes. There have been previous studies showing the effects of cosmetic
treatments on drug analysis. Jurado and authors (1997) did a study showing that the
chemical composition of various cosmetic treatments, including bleaching and dyeing hair,
have an effect on drug stability. They showed that strong basic treatments involving
ammonium hydroxide and hydrogen peroxide (H2O2), affect the hair fiber causing
alterations to the cuticle. “Ammonium hydroxide opens the scales of the cuticle to facilitate
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the entry of the other compounds, H2O2, a powerful oxidant, attacks the hair pigment and
decolorizes the hair” (Jurado et al., 1997, p. 161). Overall, the drug concentration in hair
had decreased with the use of cosmetic hair treatments.
A segmental analysis of hair can be performed on hair samples when the root end
is clearly noted. Recent and long-term drug exposure can be determined through segmental
analysis. With the known rate of hair growth in head hair (1 cm/month), the identification
and quantification of drugs and its metabolites along the length of the hair shaft can be
determined for drug history. Small segments of hair can be cut into known lengths and
analyzed for drug exposure.
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